| Author |
Kimura, Hiroshi Kanahara, Nobuhisa Sasaki, Tsuyoshi Komatsu, Naoya Ishige, Minoru Muneoka, Katsumasa Ino, Hidetoshi Yoshimura, Kazuyuki Yamanaka, Hiroshi Suzuki, Tomotaka Komatsu, Hideki Watanabe, Hiroyuki Shimizu, Eiji Iyo, Masaomi |
| Description |
Country affiliation: Japan Author Affiliation: Kimura H ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.); Kanahara N ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan Division of Medical Treatment and Rehabilitation, Center of Forensic Mental Health, Chiba University, Chiba, Japan kanahara@faculty.chiba-u.jp.); Sasaki T ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan Department of Psychiatry, Dowa-kai Chiba Hospital, Chiba, Japan.); Komatsu N ( Department of Psychiatry, Dowa-kai Chiba Hospital, Chiba, Japan.); Ishige M ( Department of Psychiatry, Satsuki-kai Sodegaura-Satsukidai Hospital, Chiba, Japan.); Muneoka K ( Department of Psychiatry, Gakuji-kai Kimura Hospital, Chiba, Japan.); Ino H ( Department of Psychiatry, Doujin-kai Kisaradzu Hospital, Chiba, Japan.); Yoshimura K ( Department of Psychiatry, Doujin-kai Kisaradzu Hospital, Chiba, Japan.); Yamanaka H ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan Department of Psychiatry, Chiba Psychiatric Medical Center, Chiba, Japan.); Suzuki T ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan Department of Psychiatry, Koutoku-kai Sato Hospital, Yamagata, Japan.); Komatsu H ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan Department of Psychiatry, Choshi-Kokoro Clinic, Chiba, Japan.); Watanabe H ( Division of Medical Treatment and Rehabilitation, Center of Forensic Mental Health, Chiba University, Chiba, Japan Department of Psychiatry, Asahi Hospital, Chiba, Japan.); Shimizu E ( Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba University, Chiba, Japan.); Iyo M ( Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.) |
| Abstract |
UNLABELLED: Dopamine supersensitivity psychosis (DSP) resulting from antipsychotic treatment is related to treatment-resistant schizophrenia (TRS), and its treatment has not been established to date. Maintaining thoroughly stable occupancy of the dopamine D2 receptor by risperidone long-acting injectable (RLAI) is one strategy for treatment. In this study, RLAI was given as an adjunctive medication to oral antipsychotic(s), which were switched partially and gradually to RLAI in 108 treatment-resistant patients for an additional 1-year follow-up in a 2-year study, and to compare the effects in 72 patients with a DSP history (DSP group) and 36 patients without this history (NonDSP group). Although both groups showed significant improvements in the total Brief Psychotic Rating Scale (BPRS) score during the follow-up period, greater improvement was observed for the DSP group than the NonDSP group. High doses (> 850 mg chlorpromazine-dose combined of oral antipsychotics and RLAI) did not significantly change in both groups throughout the study period; however, extrapyramidal symptoms, including tardive dyskinesia, were significantly improved only in the patients with DSP. This study strongly suggested that the RLAI treatment, even with only partial switching, provides relief from refractory symptoms, particularly for patients with a history of DSP. CLINICAL TRIAL REGISTRATION: http://www.umin.ac.jp/:UMIN000008487. |
